# Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke

Study · id `cardio:ct-nct07696208` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07696208](<https://clinicaltrials.gov/study/NCT07696208>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07696208

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 124 participants.

## Technical summary

Registry record NCT07696208. Randomized; double masking; primary purpose treatment. Start 2026-07-01 (anticipated); primary completion 2028-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 124 participants (planned count; ClinicalTrials.gov record NCT07696208, source copy `cardio:ctgov-nct07696208-2026-07-10`, retrieved 2026-10-26)
- Planned start: 2026-07-01 (anticipated) (ClinicalTrials.gov record NCT07696208, source copy `cardio:ctgov-nct07696208-2026-07-10`, retrieved 2026-10-26)
- Primary completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT07696208, source copy `cardio:ctgov-nct07696208-2026-07-10`, retrieved 2026-10-26)
- Completion: 2028-05-31 (anticipated) (ClinicalTrials.gov record NCT07696208, source copy `cardio:ctgov-nct07696208-2026-07-10`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07696208, source copy `cardio:ctgov-nct07696208-2026-07-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07696208-2026-07-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke
- Condition: Hemodynamic Stability
- Condition: Ischemic Strokes
- Intervention (Drug): Ciprofol
- Intervention (Drug): Propofol
- Lead sponsor: RenJi Hospital
- Lead sponsor class: OTHER
- Collaborator: Haisco Pharmaceutical Group Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: RenJi Hospital (`cardio:org-renji-hospital`)

## Provenance

Content hash: 20bad0c7f5107c55ce8ebc325a1be1196d54a04d909c5683d8fec8bbe616e58b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
